Zogenix

Pharma

UCB's Fintepla shows potential to treat a 3rd epilepsy disorder

A phase 3 trial of UCB's Fintepla, treating patients with the rare epileptic condition, CDKL5 deficiency disorder, has achieved its primary endpoint.

Kevin Dunleavy Jun 27, 2025 11:28am

epilepsy AI MRI

UCB pens multiple collabs to boost cluster seizure awareness

Aug 22, 2022 3:00pm

Dementia

UCB nabs Fintepla label expansion

Mar 28, 2022 9:18am

UCB sign

2 players vied before UCB emerged to buy Zogenix for $1.9B

Feb 1, 2022 5:24pm

UCB sign

UCB bolsters epilepsy portfolio with Zogenix buy

Jan 19, 2022 11:16am

Drugs and money sign

Pfizer, Zogenix, Catalyst, Rigel raise prices to start July

Jul 1, 2021 10:16am